 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Gemini Genomics plc
 |
Gemini Genomics plc |
 |
 |
 |
PROFILE |
 |
Gemini Genomics may one day unlock the mystery of the evil twin. The company identifies genes that may correlate with certain diseases. Gemini culls genetic samples from volunteers, with an emphasis on twins; it also obtains genetic data through deals with firms such as Celera Genomics, CuraGen, and Sequenom, which plans to acquire the company. This information may then be licensed to pharmaceutical companies to make drugs or diagnostic products, from which the firm would earn royalties. With partner Axis-Shield, Gemini has developed a diagnostic assay that can determine if a patient is predisposed to osteoarthritis. Chairman Michael Fitzgerald owns more than 30% of the development-stage firm.
COMPETITION |
 |
Genaissance Pharmaceuticals, Inc. (GNSC)
Incyte Genomics, Inc. (INCY)
Transgenomic, Inc. (TBIO)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: March
2000 Sales (mil.): 0.20
1-Yr. Sales Growth: 3.3%
Employees: 80
Revenue per employee: $2,500.00
KEY PEOPLE |
 |
Paul Kelly
CEO
Tony Ratcliffe
CFO
CONTACT INFO |
 |
162 Science Park
Cambridge Cambridgeshire CB4 0GH, United Kingdom
Phone: 44-1223-435-300
Fax: 44-1223-435-301
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |